A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans order Cy5 NHS Ester european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Decreased risk Later age of onset No risk association No MedChemExpress Daclatasvir (dihydrochloride) threat association No risk association Decreased danger of eR+ BC No danger association enhanced all round risk No danger association increased threat of eR- BC enhanced risk elevated danger No risk association enhanced risk No danger association elevated threat No threat association improved threat No risk association increased risk No danger association Decreased threat No threat association enhanced all round danger No danger association No danger association increased general danger No threat association Decreased threat of eR+ BC enhanced threat of eR- BC No risk association Decreased danger No risk association increased threat of eR+ No threat association No risk association Decreased danger of eR- BC Decreased threat of eR+ BC No risk association Decreased threat of eR+ No danger association No threat association elevated general threat Decreased overall risk No threat association No risk association enhanced risk of eR- BC improved risk improved threat improved risk enhanced risk in eR+ earlier age of onset enhanced risk (A allele) earlier age of onset (C allele) Decreased risk Decreased risk elevated threat Lowered survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 3 UTR BMPR1B 3 UTR BRCA1 3 UTR HPGD three UTR IGF-1R three UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 (Continued)miRNA locus KRAS 3 UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation improved frequency in BRCA1 carriers/no danger association enhanced threat of TNBC Decreased threat enhanced threat and poor survival earlier age of onset improved threat enhanced risk Decreased threat Decreased all round risk No threat association Decreased threat of eR+ BC No threat association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Decreased danger Later age of onset No danger association No threat association No risk association Decreased risk of eR+ BC No danger association elevated general risk No threat association elevated danger of eR- BC increased danger improved threat No threat association elevated risk No risk association increased risk No threat association enhanced threat No danger association increased threat No risk association Decreased risk No risk association increased general risk No threat association No danger association elevated overall danger No risk association Decreased risk of eR+ BC elevated danger of eR- BC No risk association Decreased risk No risk association improved risk of eR+ No threat association No threat association Decreased risk of eR- BC Decreased threat of eR+ BC No risk association Decreased threat of eR+ No threat association No danger association elevated overall risk Decreased general danger No threat association No risk association improved threat of eR- BC enhanced threat increased danger improved threat enhanced risk in eR+ earlier age of onset increased danger (A allele) earlier age of onset (C allele) Decreased threat Decreased risk improved risk Lowered survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B 3 UTR BRCA1 three UTR HPGD three UTR IGF-1R 3 UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 3 UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation increased frequency in BRCA1 carriers/no risk association elevated danger of TNBC Decreased danger elevated threat and poor survival earlier age of onset increased risk improved danger Decreased danger Decreased all round danger No danger association Decreased threat of eR+ BC No threat association increas.